Compare General Motors Company (GM) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Novavax Inc — how do they compare? General Motors Company trades at $86.96 (market cap $78.40B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: General Motors Company is far larger — about 59.8× Novavax Inc's market cap, and General Motors Company pays a 0.81% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| GM | NVAX | |
|---|---|---|
Market Cap | $78.40B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $11.19 |
52-Week Low | $54.16 | $6.22 |
Enterprise Value | $181.38B | $889.30M |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.19, down 0.88% on the day, with strong technical momentum showing bullish moving average signals. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.57 exceeding the $3.19 estimate. Recent developments include a $4.5 billion parts supply agreement to mitigate future disruptions and a renewed 20-year joint venture with China's SAIC Motor. Analyst consensus remains strongly positive with a $108.82 price target representing 25% upside potential.
GM presents a compelling investment case with attractive valuation metrics including P/S of 0.45 and EV/EBITDA of 10.35, though profitability metrics remain challenged with net margin at 1.05%. Key risks include declining profit margins from 6.33% in 2022 to 1.45% in 2025, high debt levels with debt-to-asset ratio of 46.79%, and ongoing supply chain challenges in the automotive sector.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
